Deltagen Estimates Tax Breakdown of December 2006 Dividend
, January 30, 2007
- Deltagen, Inc. (Pink
Sheets: DGEN) paid a cash dividend of $0.20 per common share on December 28,
2006 to shareholders of record as of the close of business on December 18,
2006. The Company estimates that 59.57%
of the dividend will be classified as an ordinary dividend for income tax
purposes. The remaining 40.43% of the
dividend paid to a shareholder will generally be treated first as a nontaxable
return of capital to the extent of the shareholder's tax basis in his or her
shares, with any excess amount over the shareholder's tax basis being treated
as capital gain. The Company does not
make any guarantees as to the ultimate tax treatment and advises shareholders
to consult their tax advisors.
Deltagen, Inc. is
a leading provider of drug discovery tools to the biopharmaceutical industry.
Deltagen offers access to its extensive inventory of knockout mouse lines and
related phenotypic data, which enhance the efficiency of target validation and
drug discovery. In addition, Deltagen offers target validation data in the
areas of immunology and metabolic diseases. Deltagen's products and programs
have been validated by customers and partners such as Eli Lilly & Co.,
GlaxoSmithKline, Merck & Co., Inc. and Pfizer Inc. For more information on
Deltagen, visit the Company's website at www.deltagen.com.
This press release contains "forward-looking statements,"
including statements about dividend declarations and estimated tax treatment
thereof, as well as other matters that are not historical facts or
information. These forward-looking statements are based on management's
current assumptions and expectations and involve risks, uncertainties and other
important factors that may cause Deltagen's actual results to be materially
different from any future results expressed or implied by such forward-looking
statements. There are no assurances that the Company will declare any future dividends. Deltagen undertakes no obligation to update
or revise any such forward-looking statements, whether as a result of new
information, future events or otherwise.
©2007 Deltagen, Inc. All rights reserved.